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Introduction and Specific Aims
Asthma is a chronic disease associated with inflammation and hypersensitivity of
the airways, and is clinically manifested by cough, wheeze, shortness of breath, or chest

tightness. Worldwide, approximately 300 million people currently have asthma, with
asthma accounting for 1 in every 250 deaths. 2 In the United States, asthma affects an
estimated 31.3 million Americans, 9 million of whom are children. 3 Moreover, the United

States has experienced a 300% overall increase in asthma prevalence since the 1980’s.
From 1980 to 1994, the percentage of children under 5 years with.asthma increased by an
estimated 160% and increased among children age 5-14 years by 74%.

4, 5

Asthma is

estimated to affect an additional 100 million people worldwide by 2025. 2

There is substantial evidence to support the roles that under-classification and

under-treatment of asthma symptoms play in the increasing rates of asthma morbidity and

mortality. 6-9 Asthma care that is not consistent with actual asthma severity has been
linked to poor patient outcomes.

The three major contributors to under-treatment of

asthma are: 1) Patient inability to accurately recall actual asthma symptoms; 2) Patient

inability to adhere to the asthma treatment plan; and 3) Clinician nonadherence to the
National Asthma Education and Prevention Program (NAEPP) guidelines.

In an effort to reduce the burden of asthma and improve asthma disease
management, the National Institutes of Health (NIH) and the National Heart, Lung, and
Blood Institute (NHLBI)developed national asthma guidelines through the NAEPP. 6 The

goals of these national guidelines are to narrow the gap between current knowledge and
practice and to improve the quality of life for children with asthma, with one of the

fundamental pieces focusing on classification of asthma severity.

Despite the wide dissemination of these guidelines, many studies have noted poor

compliance to and/or knowledge of the NAEPP guidelines by primary care clinicians. 6’

Disagreement among clinicians on how the NAEPP guidelines should be used and the
variability of asthma symptoms from patient to patient as well as within each patient over
time contribute to poor adherence to the guidelines. 9

.Easy Breathing(C) is an asthma management program for primary care clinicians
modeled after the NAEPP guidelines. The goals of Easy Breathing(C) are to assist primary
care clinicians with improving asthma recognition-and classification of asthma severity,

with developing a systematic, standardized approach to asthma management, and with

improving the health of children with asthma. 2
(C)
While all components of the Easy Breathing program are important in asthma

(C)
management, this study will focus on the use of the Easy Breathing Provider

Assessment, a scripted set of questions that help the clinician determine asthma severity.
This assessment uses the same frequency of symptoms as outlined by the NAEPP

guidelines. Easy Breathing(C) has been associated with a significant improvement in
clinicians’ adherence to the national guidelines, and a significant increase in asthma

recognition and care; 3 however, there is currently no evidence that the classification
scheme used on the Provider Assessment accurately classifies asthma severity or that
these subjective measures compare with the severity identified through objective
measures.

In order to prescribe appropriate therapy, clinicians rely heavily on subjective
measures such as patient reports of asthma symptoms. In addition, objective measures

such as spirometry, are limited by cost, availability, and clinician .knowledge on how to

use the equipment. In a busy practice with limited time and resources, it is essential to

have a simple method for determining asthma severity and control in the absence of

objective measures. For these reasons, it is important to determine the utility of the Easy
Breathing(C) Provider Assessment. Listed below are the questions that arose regarding this
assessment tool and the specific aims that were developed in an effort to answer these

questions:

(1) How good is the Provider Assessment at determining asthma severity?
a. Specific Aim:

To determine the sensitivity and specificity of the

six

questions on the Easy Breathing(C) Provider Assessment in determining
asthma severity. Hypothesis: Sensitivity of the six questions will be
above 50% with specificity above 80%

(2) Do clinicians use the Provider Assessment as intended?
a. Sp.ecific Aim: To assess whether or not the Provider Assessment was

used as designed for determining asthma severity. Hyoothesis: In

actual practice, clinicians will be conservative and underestimate the

asthma severity of 25% of the children

(3) How does the Provider Assessment compare to spirometry? How often
would spirometry drive a change in therapy?
a. Specific Aim: To determine how often clinician-determined asthma

severity (through use of the Easy Breathing(C) Provider Assessment)
underestimates

asthma severity as measured by spirometry.

Hyoothesis" Clinician-determined severity will underestimate severity
measured by spirometry 25% of the time.

Background

The History ofAsthma
Asthma is not a new disease. Asthma symptoms were first documented 3500

years ago in an Egyptian manuscript titled, "Ebers’ Papyrus".. Homer’s Iliad also made
reference to the word "asthma", which means, "labored breathing" in Greek. In 1190

AD, Moses Maimonides, a Spanish physician, wrote a book entitled "Treatise on
Asthma".
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During the Renaissance, the focus shifted to the actual causes of diseases such as
asthma. Jean Baptiste van Helmond, a physician from Brussels, was one of the first

physicians to link asthma to dust and seafood allergy. Although he noticed a relationship
between these triggers (as well as seasonal changes) and the onset of asthma symptoms,
he incorrectly attributed these symptoms to the blooming of roses instead of pollen from
trees and grass that pollinate within the same timeframe.

14-16

During the 17 th and 18 th centuries, physicians realized that asthma was caused by
airway constriction, or as one physician described it, "epilepsy of the lungs". v In 1698,
John Floyer classified asthma as either periodic or continued, identified a number of

triggers, and surmised that certain foods thickened the mucus and therefore worsened
asthma symptoms.

In the 19 th century, a number of findings led to improving the recognition of
asthma. R6n6 T.H. Lannec invented the stethoscope in 1816, which provided clinicians
a way to hear bronchospasm associated with asthma.

In 1852, John Sweet, who

identified bronchial inflammation as a causative factor in bronchospasm, expanded

LaEnnec’s findings by noting the relationship between cold, dampness, and changes in

weather as potential triggers of bronchospasm. 5 William Osier added to these findings
when he included mucosal edema and excessive mucus production as elements of an

asthma exacerbation. 4

In 1923, the concept of genetics as a causative factor of asthma was conceived
when. American physicians A.F. Coca and R. A. Cook described atopy and the hereditary
component associated with asthma.

They noted that atopic individuals carried a

"reaginic" antibody that led to an allergic-immune response. These findings took nearly

four decades to develop, however, in the late 1960’s a group of researchers dubbed this

"reaginic" antibody "Immunoglobulin E (IgE)" and observed that many people with
asthma had very high levels of IgE. Knowing that asthma had an allergic component led
researchers to begin investigating, allergens such as dust mites, pollens, spores, and

Reflecting on this information, it is somewhat astonishing to think that it has
taken nearly 3000 years to achieve our current understanding of asthma as a disease of

labored breathing caused by airway constriction, bronchospasm, with an allergic and

genetic component, that can be intermittent or continuous. In fact, during the 1960’s, the

only way to confirm the inflammatory component of asthma was to conduct post mortem
examinations.

7, 8

Furthermore, although cellular changes have been thought to play a

role in asthma since the late 19 t century, the 1962 American Thoracic Society definition

of asthma was limited to "recurrent episodes of airflow limitation that are usually

reversible...,,14, 16 In 1997, the NHLBI updated this definition to:
Asthma is a chronic inflammatory disorder of the airways in which many cells
and cellular elements play a role... In susceptible individuals, this inflammation
causes recurrent episodes of wheezing, breathlessness, chest tightness, and
coughing, particularly at night or in the early morning. These episodes are

usually associated with widespread but variable airflow obstruction that is often
reversible either spontaneously or with treatment. The inflammation also causes
an associated increase in the existing bronchial hyperresponsiveness to a variety
9
0 f stimuli.

Today, asthma is recognized as more than just a specific set of causes and clinical

consequences; it is a complex disease process that varies from person to person as well as
within each person over time. This advance in the knowledge of asthma pathophysiology

has transformed the way in which people with asthma are treated.

Treatment for Asthma
Although strides were being made in the identification of triggers and other
causative factors, asthma treatment remained in its early stages through the 19 t century,

and traditionally consisted of prescriptions of chicken soup, sexual abstinence, and
various herbal remedies.

17

It was not until the early part of the 20th century that

antispasmodics were used regularly to counteract an asthma exacerbation. For example,
in the early 1900’s, adrenaline was used to effectively treat acute asthma episodes. In the

20-30 years that followed, theophylline and cortisone drugs were developed, and

demonstrated effectiveness in treating asthma symptoms; however, clinicians did not
understand how these drugs worked or why they relieved asthma symptoms.

From 1970 to the 1990’s, innovative research programs produced breakthroughs
in

asthma

therapy including improved bronchodilators,

beta-agonists,

anti-

inflammatories, and leukotriene modifiers. Advancements in asthma therapy continue

today leaving clinicians with the daunting task of keeping abreast of the updates. This
reinforces the need for repeated dissemination of these advancements through such
means as the national guidelines.

Asthma "s Impact on Public Health

Asthma prevalence, morbidity, and mortality are increasing which make it a

priority in governmental health strategies. 2 In fact Healthy People 2010, a government
health initiative, has a number of objectives related to asthma. These objectives aim to
decrease the burden of asthma by decreasing the number of deaths, hospitalizations,

Emergency Department visits, activity limitations, and number of school/work absences
related to asthma; to improve asthma management by increasing the amount of formal
education given to patients with asthma and the number of children receiving appropriate

asthma care according to the NAEPP guidelines; and by establishing improved
surveillance systems to track asthma prevalence, morbidity, and mortality rates. 2 This

last objective to enhance data collection methods will improve the recognition of factors
that increase the burden of asthma, that are a barrier to appropriate asthma management,
and that identify disparities among various ethnic groups and social classes.

There are a number of theories that attempt to account for the dramatic rise in

asthma prevalence over the last 30 years. Improved recognition and surveillance of

asthma plays a role in these increases; however, the overall increases in asthma

prevalence are too great for this one explanation alone. 4

One theory, the "Hygiene

Hypothesis" attributes cleaner ways of living, such as overuse of household cleaners,

antibiotics, and energy-efficient, airtight housing, as possible sources of increasing
airway sensitivity. This hypothesis presumes that these factors compromise a child’s
immune system by reducing exposures to early childhood infections, making children
more susceptible to asthma later in life. 5’2

Dr. Thomas Platts-Mills suggests a different theory, which I will label the
"Sedentary Hypothesis". This hypothesis claims that some of the increase in asthma
prevalence can be attributed to a more sedentary lifestyle in today’s children. This
lifestyle creates a three-fold issue. First, children of today spend more time indoors than
thirty years ago.

This means more TV watching, playing video games, and other

sedentary activities that have led to a decline in physical activity and thus, a decrease in
resistance to airway inflammation caused by allergen exposure. 21 Second, rising rates of

obesity in children have been attributed to a decrease in physical activity levels. There is

speculation that obesity causes constriction (or compression also known as
"pseudoconstriction") of the airways that increases the likelihood of childhood asthma.
Third, by remaining indoors for longer periods of time, Platts-Mills hypothesizes that
children have higher exposure rates to indoor allergens such as dust mites, molds, and
cockroaches causing an increase in allergy sensitization and asthma. 5’22
While the underlying factors responsible for the increase in asthma rates are not

known, the fact remains that asthma is a growing concem that affects the quality of life,
not only for the child with asthma, but also for the family of that child. One study, done

in New Delhi, India, noted that 65.4% of the children (with asthma) in their study had
some restriction on their play activities because of asthma, 59.8% had restrictions in other

physical activities, median school absenteeism ranged from 4 to 27.5 days (depending on

severity of exacerbation) in the preceding 6 months because of events related to asthma,
and 26.4% of the fathers and 50% of mothers reported a median of 4 missed days of work
in the preceding 6 months for the same reason. Overall, 19.4% of parents reported

limiting family activities and 16.1% made special adjustments in their lifestyle because of

the adverse impact of asthma. 23 Similar findings have been reported elsewhere. 24’

a5

According to Maier, et al., on average, 30% of children with mild asthma symptoms
complain of sleep disturbances, school absenteeism, and activity limitations because of

asthma symptoms whereas approximately 79% of children with severe symptoms report
these same limitations. 24 Juniper confirms the negative effects that uncontrolled asthma

symptoms have on quality of life. 25

Not only is the quality of life for a child with asthma affected, but uncontrolled
asthma can lead to death. In 2000, 223 children died from asthma in the U.S. Mortality
rates are highest in non-Hispanic blacks (200% higher than non-Hispanic whites) and

females (40% higher than males). 26 Although asthma deaths are rare among children, it
may be possible to further reduce these rates by following the national guidelines,

including a comprehensive patient asthma education program. 9, 15, 25, 27, 28
Other studies have analyzed the relationship between adhering to specific sections

of the NAEPP guidelines and the reduction in morbidity rates.

In particular, the

American Lung Association asserts that if every child with asthma is protected against

influenza, a 60% reduction in hospital stays could be achieved. 29 In the adult population,
Paltiel, et al. estimate a gain of $13,500 per quality-adjusted life year and $7.50 per

symptom-free day when inhaled corticosteroids are used as recommended by the NAEPP
guidelines. 3 Another study found that using patient education as part of an asthma
management program may reduce office visits, improve inhaled corticosteroid use,

improve lung function (FEV), and improve overall quality of life. 3 Based on these

findings alone, the cost associated with mismanaging asthma symptoms is high but may
be improved by following the NAEPP guidelines.

Inadequate asthma management is costly. Missed school days alone represent an
indirect cost of nearly $1.5 billion each year. 32 Direct costs for treating asthma in those

less than i 8 years of age have been estimated at $3.2 billion, per year (in 1994 dollars). 3z

Despite the downward trend in pediatric health care expenditures, a significant imbalance
persists between children with and without asthma. For example, the median annual
health care expenditures for asthma in 1987 were $1129 per child with asthma per year
versus $468 per child without asthma. 33 In 1996, the median annual health care

expenditures for children declined to $475 per child with asthma per year versus $191 per
child without asthma. 34 Although this represents an approximate 40% decline in the
median annual health care expenditures for children during this time frame, the

disproportionate cost between children with asthma versus those without has remained
constant at 40%.

In addition, median annual expenditures for prescription drugs are significantly
disproportionate between children with asthma ($75/year) versus children without asthma
($6/year), with prescription drugs accounting for almost 40% of all asthma-related health
care expenditures for children. 34 Even along the asthma continuum, children with asthma

who have the highest health care expenditures cost 28 times more than children with
asthma with the lowest expenditures. 34 Some experts estimate that half of this economic

impact is related to severe asthma exacerbations, not to the costs of managing chronic,
stable asthma. 4

10

National Guidelines

In an effort to reduce the growing burden asthma has on the U.S. population, the
NIH and the NHLBI instituted national asthma guidelines in 1991. These guidelines
serve a number of purposes.

First, the guidelines describe the relationship between

airway inflammation and its management, including the pathophysiology of asthma as a
chronic inflammatory disorder of the airways, the role of the environment in the

provocation of airway inflammation, and the variability of airway inflammation and

hyperresponsiveness. Second, the guidelines outline the four key components of asthma

therapy: assessment and monitoring, pharmacologic therapy, control of factors
contributing to asthma severity, and patient education. Third, the guidelines illustrate a

stepwise approach to asthma management. 9
Since the development of the national guidelines, there have been advances in the

recognition, classification, and treatment of asthma. To keep pace with these emerging

standards, the NAEPP guidelines were updated in 1997 and again in 2002. To facilitate
clinician adherence, the guidelines for the diagnosis and treatment of asthma have been

organized into a systematic, stepwise approach and widely distributed. 35
Despite this wide dissemination, primary care providers’ adherence to the
guidelines remains low. 6"8 Barriers to implementing the guidelines reported by clinicians
include a lack of awareness or familiarity with the guidelines and a perceived lack of

agreement among clinicians, especially in regard to the safety of inhaled corticosteroid

use.7, 13, 36 Even if the clinician is comfortable with prescribing corticosteroids, he or she
may encounter parental concerns regarding the safety, efficacy, and actual need for these
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medications. Both clinician and parent apprehension directly affect the accuracy in
which the clinician classifies asthma severity and treats the child. Moreover, the

classifications of symptom frequencies were based on consensus opinion and are not
evidence based. To date, this classification scheme has not been validated.

’

37

Clinicians also report a lack of self-efficacy in following the guidelines. This

particular issue may be improved with practical training and education in the use of the

guidelines.7,

,

13

Finally, clinicians report a lack of outcome expectancy -the underlying

questions are whether or not following the guidelines will make a difference and if the

patient will comply. l

One study noted a low level of agreement among pediatric asthma specialists
when evaluating interrater reliability of this classification scheme. 36 The authors suggest
three possible explanations for the variability in classifying asthma:

variability in

interpretation of asthma symptoms, variability in interpretation of pulmonary function
test results, and variability in the importance placed on symptoms vs. pulmonary
function. 36 Other studies suggest that difficulties with patient-to-clinician communication,

due to the patient’s cultural beliefs, language barriers, and psychological risk factors,
limit the clinician’s ability to adequately classify asthma severity. 38-4 Specifically,
communication between a clinician and a patient or family member with limited English

proficiency (LEP) and/or culturally diverse backgrounds must take into account how this
information is conveyed and how it is received. 4 Inadequate communication between a
clinician and patient can lead to misdiagnosis; or in the case of asthma- misclassification

of asthma symptoms. 4
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Whether misclassification occurs due to miscommunication, the variability of
asthma symptoms, or parent/clinician apprehension regarding the use of appropriate

therapy, the results are the same: inadequately controlled asthma symptoms interfere
with the child’s and parent’s quality of life, and have a significant impact on morbidity,

mortality, and the economic costs associated with asthma.
Another barrier to the use of the NAEPP guidelines is length. The original 1991
version included 10 sections, multiple subsections, figures, tables, and flowcharts, which

together totaled 136 pages. The 1997 version was reduced to 4 sections, multiple
subsections with multiple figures, tables, and flow charts and totaled 52 pages.

It is

reasonable to assume that this length is a barrier to the busy clinicians’ examination and

implementation of the guidelines.

Easy Breathing(C)
Easy Breathing(C) is a disease management program that has taken the lengthy
NAEPP guidelines and pared them down to four essential components. The first
component consists of a 4-question previously validated survey that is given to children

between the ages of 6 months to 18 years (Figure 1) In addition, the parent answers
questions related to family history of asthma, and other demographic information that

may relate to asthma severity and/or control (ethnicity, gender, age, living conditions and
location, as well as exposure to common triggers).
The clinician reviews this information with the parent and child and performs a

physical examination to supplement the survey responses. In conjunction with this

information, the clinician determines asthma severity through the use of a program-

developed written instrument (the Provider Assessment) patterned after the national

13

guidelines.

The Provider Assessment, for newly diagnosed asthma, consists of six

questions regarding the frequency of daytime symptoms, noctumal symptoms, exercise

impairment, use of beta-agonists, use of prednisone therapy, and school absenteeism in
the past year. (Figure 2) Each question has four possible frequencies that correlate with
the overall asthma severities of Mild Intermittent, Mild Persistent, Moderate Persistent,

and Severe Persistent disease. Program staff direct the clinician to choose the highest

symptom frequency chosen to determine asthma severity. A comprehensive asthma
treatment plan is then derived from a severity-specific treatment selection guide. 42 Once
this process is completed, the child has been surveyed, examined, a diagnosis has been

established, severity has been defined, and the child has been sent home with a written
treatment plan in hand.

Easy Breathing(C) has been associated with an improvement in clinician knowledge
and adherence to the NAEPP guidelines. 3 In a 2002 report, Easy Breathing(C) was
associated with a substantial increase in the adherence to guideline-specific use of inhaled

corticosteroids, with a decrease in oral corticosteroid therapy for all severities, an
increased use of nonsteroidal inhaled anti-inflammatory drugs for mild asthma, and an

improvement in subspecialty referral for children with severe persistent disease. 3

Furthermore, all clinicians .believed that the Easy Breathing(C) training had
improved their knowledge of asthma, although midlevel practitioners were more
convinced than physicians that Easy Breathing(C) had improved their ability to diagnose

asthma. This was further illustrated through the results of follow-up tests where midlevel

practitioner "applied knowledge" scores continued to improve while physician scores
remained constant.

3
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Pulmonary Function Tests
Despite the improvement in clinician knowledge of and adherence to the national
(C)
guidelines, Easy Breathing relies on subjective measures to classify asthma severity. A

number of studies have confirmed the need for objective measures.

’

43-50

The World

Health Organization notes, "Patients with asthma frequently have poor recognition of
their symptoms and poor perception of the severity, especially if their asthma is severe

and longstanding." In addition, physical examination may be normal while objective
measures reveal significant airflow limitation.5.

The NAEPP guidelines recommend the use of tests of pulmonary function to
establish airflow obstruction, establish reversibility, and to exclude alternative

diagnoses. 9 These objective measures serve two main purposes" 1) to confirm the

subjective findings of asthma symptoms, and 2) to properly classify asthma severity.
The most widely used objective measure in the office setting is the peak flow
meter. Peak expiratory flow rate (PEFR) is a simple, inexpensive method of detecting
airflow obstruction; however, its limitations are extensive. First, PEFR reflects large

airway caliber; obstruction in asthma primarily affects the small airways. 5 Second, PEFR
is effort dependent and may be difficult for younger children to use. 45’ 52 Third, diurnal
variation in PEFR may skew results depending on the time of day the measurements are

recorded. Fourth, discrepancies of 50 L/min between various PEFR devices can exist and
the accuracy of the PEFR device deteriorates over time, even after as few as 200 uses.

Fifth, the correlation between PEFR and other measures of airway obstruction, such as

spirometry, is limited. 45
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Even when used as a monitoring device, PEFR meters are inaccurate. Studies

show that unsupervised PEFR recordings are inaccurate, fabricated, and difficult to

reproduce.45, 52, 53 This is not to say that PEFR is entirely without merit.

When used in

conjunction with a comprehensive educational program that encourages patients to

recognize the signs and symptoms of an impending exacerbation, PEFR can assist the
patient and clinician to recognize and treat an asthma exacerbation early on.

45

According to NAEPP guidelines, the "gold standard" for objective measurements
of asthma is spirometry. The guidelines recommend that spirometry be performed: "1) at
the initial assessment; 2) after treatment has stabilized symptoms and peak flow (to

document a baseline of"normal airway function"); and 3) at least every one to two years
when asthma is stable, more often when asthma is unstable, or at other times the clinician
believes it is necessary. ’’9

Spirometry is held in higher regard than PEFR monitoring, but it is not without its
own challenges. First, trained personnel are required to administer the test and interpret

the results.

Second, spirometry equipment must meet or exceed the requirements

proposed by the American Thoracic Society, be calibrated appropriately, and include
reference values appropriate for the population of subjects being tested. Third, like

PEFR, spirometry is effort dependent and further limited by the inability of young
children (<5 years) to perform the maneuver. Fourth, spirometry does not differentiate
between Mild Intermittent and Mild Persistent disease and, like the classification scheme
for frequency of symptoms, spirometry measures are not evidence based.

Fifth,

spirometry is limited by the lack of available spirometry equipment in private practices,
lack of appropriate training, and the cost associated with such equipment. 2
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Despite these limitations, the benefits of spirometry are numerous.

First,

spirometry offers a relatively simple, noninvasive way to diagnose airway obstruction
and to classify baseline asthma severity. It requires approximately 20-30 minutes when

performing pre- and post-bronchodilator testing and provides an immediate review of
flow volume curves to determine effort, quality, and reproducibility of each maneuver. 54’
55

Second, because respiratory symptoms correlate poorly with actual disease severity,

using spirometry allows the clinician to compare subjective symptoms with objective

lung function measurements. Furthermore, unlike PEFR, spirometry is able to detect
56
mild disease as well as differentiate between disease of the small and large airways. 54’

Third, the small airways are clearly linked to the pathogenesis of asthma, are considered

the "quiet zone", and thus, any damage done to the small airways may be undetected
without the use of spirometry. 57 Fourth, because of its precision in assessing the severity

of lung disease, spirometry can be used to monitor patient progress and/or deterioration.

56

In summary, asthma is a common and costly disease. National guidelines are
available but not widely followed leading to under-diagnosis and under-treatment of

asthma severity. The use of subjective measures alone may be insufficient in properly

classifying asthma severity, however, objective measures are not always readily
(C)
available. Therefore, it is important to determine 1) If the Easy Breathing Provider

Assessment is a sensitive and specific method for determining asthma severity; 2) If
clinicians use the Provider Assessment as intended; and 3) How often clinician(C)
determined asthma severity (through use of the Easy Breathing Provider Assessment)

underestimates asthma severity as measured by the "gold standard" (spirometry).

17

Methods

Subjects
The study population was a subset of the "newly diagnosed" enrollees in Easy
(C)
Breathing who had complete spirometry data available. Gender, age, and ethnicity data

were collected from the Easy Breathing Survey.

The Easy Breathing(C) Provider Assessment
The frequency of respiratory symptoms was evaluated using the Provider

Assessment, a program-specific written instrument completed by the clinician. This
instrument consists of six questions pertaining to the frequency of daytime, nocturnal,

and exercise induced symptoms as well as use of medications and school absenteeism
related to asthma. (Figure 2) These symptom frequencies are then used to assess disease
severity. Each clinician received training on appropriate use of the Provider Assessment,
which included classifying asthma severity based on the most severe step in which any
clinical symptom occurs. 9

Spirometry

Spirometry was performed pre- and post-bronchodilator (Albuterol 180 mcg
inhaled with spacer) using spirometers that conformed to ATS standards. All participants
were required to perform reproducible lung function tests (by ATS standards). Predicted

values were based upon those set forth by the third National Health and Nutrition
Examination Survey (NHANES III). For the purposes of this study, a "new" diagnosis of

asthma was considered when a child had not previously been diagnosed with asthma, and
after other possible diagnoses were excluded (following spirometry).

18

Analyses
(C)
Each question from the Easy Breathing Provider Assessment was examined

individually to determine if there were any questions that were of limited value in
classifying asthma severity.

Next, logistic regression analyses were performed to

determine whether a combination of fewer than six questions would be sufficient in

determining asthma severity. Sensitivity and specificity were calculated by comparing
how often the frequency of symptoms matched the severity selected for each individual

question. For example, if a child was classified as having Mild Intermittent disease and
their symptom frequency was selected from that severity column on the Provider

Assessment, then the disease severity and symptom frequency matched for that question.
Sensitivity and specificity were calculated for each question and then for
combinations of 2 questions. For example, sensitivity was calculated by using the number

of children who had their highest symptom frequency within the Mild Intermittent

category and who were diagnosed with that severity, out of the overall number of
children with their highest symptom frequency within the Mild Intermittent category (see

Table 3a). Specificity was calculated in a similar manner, but using the number of
children who did not have their highest symptom frequency in that category

.and who

were not classified as having Mild Intermittent disease, out of the total number of
children who did not have their highest symptom frequency in the Mild Intermittent

category.
The likelihood of a child having all 3 or 4 questions chosen from the same cohmm
was unlikely given the variation in symptom frequencies. Therefore, sensitivity and

specificity for 3 and 4 questions were not calculated. However, the percentage of
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children who had their highest symptom frequency chosen from the first 3 or 4 questions
was analyzed. This analysis provided a means of determining the percentage of children

who could be captured using the fewest number of Provider Assessment questions.

Frequency analysis was then conducted to determine how often symptom frequencies
accurately reflected the overall asthma severity. For example, how often were children
with a given disease severity likely to exhibit symptoms consistent with that severity?

Were there particular symptoms that better reflected a given disease severity?

Next, clinician chosen severity was compared to the "gold standard" of
spirometry. Kappa tests were used to measure concordance between the two. Kappa
measures were interpreted as follows: < 0.40 indicated poor agreement, 0.40-0.75

indicated moderate agreement, and > 0.75 indicated excellent agreement. 36 In addition,

frequency and chi-square analyses were performed to determine how often spirometry
would generate a change in therapy (i.e. how often were children under-diagnosed

through subjective measures).

Spirometry does not differentiate between Mild

Intermittent and Mild Persistent disease, and therefore these two categories were
combined to allow for equal comparison between clinician-determined severity and

severity determined by spirometry.

Classification of Mild Intermittent and Mild

Persistent disease were then separated out based on the number of children known to be

in each category.

A sub-analysis was conducted to compare the clinician-determined severity to the
asthma severity determined using the program guidelines. A Kappa test was performed to
measure the concordance between severity chosen and severity indicated by symptom

frequency.
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Crosstabs were used to determine the number of children not on "appropriate"

therapy. Children in the study population were not on anti-inflammatory therapy at the
time of spirometry testing, and therefore actual medications prescribed were not used.

Instead therapy was considered "appropriate" when spirometry severity was equal to or
less than clinician-determined severity. It was assumed that if the clinician chose "Mild
Persistent" disease but spirometry measures were consistent with "Moderate Persistent"

disease, the child was "under-classified" and therefore, not on appropriate therapy. This

method of analysis was based on NAEPP recommendations to classify individuals at the
9
highest severity in which any symptom or objective measurement occurs and was based

on the assumption that prescribed therapy was consistent with the clinician-determined

disease severity. The percentage of children not on appropriate therapy was then stratified

by age, gender, and ethnicity and analyzed using chi-square tests.

A cost savings analysis, based on clinician-determined vs. spirometry-determined
severity was used to determine the economic impact of under-classification and undertreatment of asthma severity. Several assumptions were made in order to determine cost

savings associated with under-classification of symptoms. First, it was assumed that
under-classification of asthma severity also meant under-treatment of asthma symptoms,
for the same reasons as noted previously. Second, it was assumed that the frequency of

nocturnal symptoms was directly correlated to inadequate prescribing methods of inhaled
corticosteroids. Nocturnal symptoms were used because, in this study, this question was
most affected by under-classification. This was done in order to average a cost savings of
$7.50 per symptom free day as suggested by Paltiel, et al. 3
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Third, using the symptom frequencies as outlined on the Provider Assessment

(Figures 2 and 4), frequencies were converted in order to delineate the average number of

days/month that a child had symptoms for each asthma severity. In order to estimate the
number of symptom-free days that a child would have gained if on the appropriate

therapy, it was assumed that a child’s symptom frequency would drop by at least one
frequency category if on the appropriate therapy. For example, a child with Moderate
Persistent asthma, according the NAEPP guidelines, could experience symptoms 8-16

times/month, (average of 12 days/month). With appropriate therapy, symptom frequency
would be expected to decrease an average of 5 days/month, by decreasing this child’s

symptom frequency by at least on frequency category (i.e. from Moderate to Mild
Persistent disease). Therefore, that child would have gained 7 symptom-free days/month.
Results

Demographics of Study Population
Since 1998, Easy Breathing(C) has recruited 10,655 children between the ages of 6

months to 18 years from six urban clinics in the city of Hartford, CT; 4,915 of these
children have physician confirmed asthma. Of these children, 2,138 were identified as

"newly diagnosed". A subset of these children (n

201) had complete spirometry data

available. (Figure 3)

The distribution of children within this study revealed a slightly higher percentage
of males (54%) vs. females, children less than 10 years of age (53%) vs. those over 10

years of age, and children of Hispanic origin (57%) vs. non-Hispanics. Non-Hispanic
children included those of African American (27%), White/Caucasian (7%), and "other"

(9%) ethnicities. Distribution of children by gender, age, and ethnicity showed little
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variation within each of the asthma severities. (Table 1) The cohort demographics were

similar to those found in the Easy Breathing program overall. (Table 2)

Specific Aim #1" To determine the sensitivity and specificity of the six questions on the

Easy Breathing (C) Provider Assessment in determining asthma severity. Hypothesis:
Sensitivity of the six questions will be above 50% with specificity above 80%

Analyses of sensitivity and specificity were conducted to determine if any of the
Provider Assessment questions were of limited value in classifying asthma severity.

Table 3 shows the sensitivity and specificity of each Provider Assessment question by
clinician-determined severity. Sensitivity of the Provider Assessment questions was

above the 0.50 level 42% of the time with specificity over the 0.80 level 50% of the time.
Sensitivity was highest among the Mild and Moderate Persistent severities while

specificity was highest for Mild Intermittent and Severe Persistent disease.
Provider Assessment Questions

Questions related to daytime and noctumal symptoms have the most significant
impact on each of the four disease severities (P<.0005). The question related to school
absenteeism was also significant for all 4 severities (P<.05) whereas exercise impairment
was significant for the 3 persistent severities (P<.03). The question regarding Prednisone
use was statistically significant (P=.0031) for Severe Persistent disease whereas the

question related to Beta-agonist use was statistically significant for both Moderate and

Severe Persistent (P=.0072 and .0079 respectively).
Logistic regression of all six questions supports the statistical significance of the
first two questions. (Table 4) Exercise impairment was marginally significant for Mild

Intermittent and Mild Persistent disease (P=0.07), but because it demonstrated statistical
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significance for all severities at the univariate level, it was reserved for further analyses.
School absenteeism was significant for the three persistent categories (P<.0085).
Prednisone and Beta-agonist use were no longer significant for any of the disease
severities and were therefore removed.

Combinations of two questions (using daytime, nocturnal, and exercise

impairment questions) improved sensitivity and specificity across all severities and
statistical significance was maintained for all three combinations. (Table 5) This finding

reflects those of other studies" asthma cannot be identified by any one symptom. 1, 49, 58
This was also confirmed by examining the frequency of symptoms by asthma severity.

Table 6 shows these results. Children diagnosed with Mild Intermittent disease either
had no symptoms or symptoms that were consistent with the NAEPP classification of
Mild Intermittent disease. For the majority of symptoms, children with Mild Persistent
disease tended to have symptoms that were consistent with Mild Intermittent disease;

however, exercise impairment appeared to have the most impact on whether or not these
children were classified as having Mild Persistent disease.

Children with Moderate and Severe Persistent disease appeared to have no pattern

in which symptom frequencies fell. Symptom frequencies were almost evenly spread
over the various severities, however, Moderate Persistent disease was most affected by

nocturnal symptoms, exercise impairment, and school absenteeism; Severe Persistent
disease was most impacted by noctumal symptoms.

Frequency analysis was used to determine the percentage of children that could be
captured using the fewest number of Provider Assessment questions. Overall, only half of
the children answered the question about Prednisone use, and only 32% had answered the
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question about Beta-agonist use. Furthermore, the use of Prednisone was the highest

frequency of symptoms for only 3 (1.5%) children. Clinicians did not use this question as
the determining factor to determine asthma severity for these 3 children. The question on
Beta-agonist use had the highest frequency of symptoms for 5 (2.5%) children, and
similar to the question on Prednisone use, clinicians did not use this question to
determine disease severity for these 5 children. Using only the four remaining questions,

between 94-100% of the children had their maximum frequency of symptoms within one
of those four questions. Eliminating school absenteeism resulted in a considerable drop in

the percentage of children captured. (Table 7)

Specific Aim #2: To assess whether or not the Provider Assessment was used as designed

for determining asthma severity. Hypothesis: In actual practice, clinicians will be
conservative and underestimate the asthma severity of 25% of the children

Table 8 shows moderate agreement between clinician-determined and program-

determined asthma severity (K=0.4362). Despite this level of agreement, asthma severity
was underestimated by as much as 47% for those children with Moderate Persistent

disease.

Specific Aim #3: To determine how often clinician-determined asthma severity (through
use

of the Easy Breathing(C) Provider Assessment)

underestimates asthma severity as

measured by spirometry. Hvlothesis: Clinician-determined severity will underestimate
severity measured by spirometry 25% of the time.

Concordance between clinician-determined versus spirometry-determined asthma
severity was poor (K=0.1089) with 31% of children not on appropriate therapy. (Table 9)
The children in this study were not receiving inhaled corticosteroid (ICS) therapy at the
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time of spirometry. Even if they had been on therapy, the results would have been

minimized: therapy was considered to be "inadequate" when spirometry severity was

greater than Clinician-Determined severity.

Had the child been on ICS therapy,

spirometry severity would have decreased, not increased.

Not surprisingly, children who were classified as Mild Intermittent were most
likely to be under-diagnosed (symptoms can only increase in frequency). The percentage
of children on appropriate therapy increased as severity increased; however it should be
noted that all children with Severe Persistent disease had to be on "appropriate therapy"

by virtue of the definition used, i.e. spirometry severity cannot be anything but less than
or equal to Severe Persistent disease.

Appropriate Therapy

Table 10 shows the percentage of children on appropriate therapy stratified by

gender, age, and ethnicity. The number of males versus females on appropriate therapy
was almost equal (68% versus 69% respectively). Although only marginally significant

(P=.06), children 10 and older were more likely to be on appropriate therapy. In contrast,
Hispanics were nearly twice as likely as non-Hispanics to be on appropriate therapy

(P=.02).
Economic Impact

To demonstrate the potential cost savings associated with appropriate
classification of asthma severity using the Provider Assessment, consider nocturnal

symptoms

the symptom most affected by under-classification in this study. For this

study population, 17% of children with Mild Persistent disease had symptom frequencies
consistent with Moderate Persistent disease; 5% of children with Mild Persistent disease
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had symptom frequencies consistent with Severe Persistent disease; and 24% of children
with Moderate Persistent disease had symptom frequencies consistent with Severe

Persistent disease. This means that for this one question alone, 22% of children with
Mild Persistent disease and 24% of children with Moderate Persistent disease were

under-classified.
These findings show that a child with Mild Persistent asthma had nocturnal

symptoms an average of 5 days/month, a child with Moderate Persistent asthma had
noctumal symptoms an average of 12 days/month, and a chil.d with Severe Persistent had

noctumal symptoms an average of 22 days/month. Taking into consideration the children
with Mild and Moderate Persistent disease that were under-classified (Table 11), a total

of 11 children with symptom frequency of 12 days/month would each have gained 7

symptom-free days/month, or a total of 924 symptom-free days/year; a total of 21
children with symptom frequency of 22 days/month would each have gained 10

symptom-free days/month, or a total of 2,520 symptom-free days/year. For these 32
children, using $7.50 per symptom-free day, a conservative estimate of the cost savings
that could be gained if these children had been on appropriate therapy is $25,830 each

year. (Figure 4) It should be noted that because actual medication therapy was not

reviewed, it was assumed that clinicians chose therapy consistent with the asthma

severity they assigned:
Discussion

Demographic Differences
Unlike other studies that suggest children of Hispanic ethnicity are less likely to

receive appropriate therapy compared to their non-Hispanic peers,4’ 9, 60 the findings of
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this study demonstrate that Hispanic children were twice as likely to receive appropriate

therapy when compared to non-Hispanic children. Although the reasons behind these
findings are unknown, it could be speculated that by offering a Spanish version of the

Easy Breathing(C) Survey and written Asthma Treatment Plan, this program helps to gap
the language barrier often experienced by children and parents of limited English

proficiency; however, African American and White/Caucasian children and their parents
also received these tools in their "native" English language. It could also be speculated

that because Hispanics within this population have been shown to be higher utilizers of
medical services, 6 they may have more opportunities to be placed on appropriate

therapy. There are no available data to support or refute these speculations. Only future
studies, which focus on this specific issue, may provide the answer.
Validation

(C)

of the Easy Breathing

Provider Assessment

Although there are no known studies that evaluate the validity of the NAEPP
classification scheme, other studies have looked at self-reported asthma symptoms in

comparison to other measures such as bronchial challenge tests and clinician diagnosis;
both of which have been found to have low sensitivity with moderate-to-high specificity.
43, 49, 62-64

Because the Easy Breathing(C) program has had positive effects on other aspects

of guideline implementation 3, a higher sensitivity and specificity was estimated than
what these studies have suggested. Overall sensitivity and specificity for the Easy

Breathing(C) Provider Assessment was not as high as hypothesized (0.50 and 0.80

respectively); however, for an instrument to be useful, one must go beyond the sensitivity
and specificity of individual questions to determine if the combination of questions asked
are a valid means of determining asthma severity. 58 Use of the first four questions on the
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Easy Breathing(C) Provider Assessmem achieved this by demonstrating statistical
significance for the majority of the severities, and with an average of 96% of children
with asthma captured by these four questions.

It is interesting to note that sensitivity was highest between the two "central"
disease categories of Mild and Moderate Persistent disease, whereas specificity was

highest for the "outer" categories of Mild Intermittent and Severe Persistent disease. One

may assume that because the two latter categories had the highest percentage of children
who were accurately classified, they would also have the highest number of "tree

positive" rates (i.e. high sensitivity). These findings indicate the opposite" the higher the

percentage of children accurately classified, the lower the probability that a symptom was
present in any other symptom frequency category. For example, looking at Table 3,
sensitivity (true positives) was marginal for the Mild Intermittent and Severe Persistent
categories (.41 and .56 respectively) whereas specificity was high (.97 and .92

respectively). The odds ratio also reflect that children within these categories are more
likely to have symptoms within their respective categories than in any other categorythose children with Mild Intermittent disease were nearly 20 times more likely to have

daytime symptoms consistent with that severity category than with any other category.

Questions related to Prednisone and/or Beta-agonist did not add value in
determining a new asthma diagnosis. Use of these medications may be a better indicator
of asthma exacerbation and control than of actual severity, and therefore a determining
factor of asthma control for those children with previously diagnosed asthma. If a child
were in fact "newly" diagnosed with asthma, there would be no reason for him/her to
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need these medications, unless these two questions were a reflection of previous

misdiagnosis (i.e. bronchospasm, reactive airway disease).

Easy Breathing(C): Clinician-determined versus Program-determined Severity
Moderate concordance between clinician-determined versus program-determined

severity may be explained in two ways. First, evidence shows that clinicians are reluctant
to classify asthma severity, especially for the higher severities. 8 This reluctance may be

attributed to lack of knowledge, self-efficacy, and/or outcome expectancy on the part of
the clinician and, for this study, is most apparent in children diagnosed with Moderate

Persistent disease. According to my analysis, 47% of children with Moderate Persistent
disease exhibited symptom frequencies consistent with Severe Persistent disease, and

therefore may be on inappropriate therapy.

Second, it is possible that the frequencies for each symptom, as outlined by the
national guidelines, do not accurately match actual symptom frequencies. Although this

study examined the overall accuracy of these symptom frequencies, it was impossible to
determine what frequencies were needed to improve classification of asthma severity.

Future studies are needed to evaluate the symptom frequencies set forth by the NAEPP
guidelines and used in the Easy Breathing Provider Assessment.
The Economic Impact of Under-classification and Under-treatment
Previous studies suggest that under-classified asthma symptoms are directly

correlated with poor patient outcomes and a substantial increase in financial burden. 23’ 33,
34

In contrast, once asthma symptoms are controlled with appropriate therapy, symptom

frequencies often drop by at least one frequency category, and quality of life improves. 25’
37,65
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This study replicates and extends the findings of other studies: the economic

impact associated with under-classifying asthma seventy is substantial. 23, 33, 34 This study

demonstrated a cost savings of $25,830 for one under-classified symptom for only 32
children. The total cost savings associated with improving recognition and classification

of asthma severity could be substantive. In addition to this cost benefit, had the clinicians
used the Provider Assessment as intended, these children may have had improved

symptom control and improved quality of life. These findings confirm the need to follow
the NAEPP guidelines.
Limitations
(C)

This study used a small sample size of Easy Breathing participants. In addition,

Easy Breathing(C) represents children who live in the city of Hartford, who are from a
mostly minority background, and who may not receive medical care by one specific
clinician.

These issues cause limitations not only for this study but also for the

probability of these children receiving consistent healthcare by the same clinician. The

clinician(s) seeing these children may not have the full representation of asthma
symptoms, exposure to triggers, and previous history of asthma-related issues such as
previous medications prescribed, symptoms associated with exacerbation, and
hospitalizations for asthma. Without this information, accurate classification of asthma

symptoms may be difficult.
Furthermore, Easy Breathing relies on the patient/parent to accurately recall
asthma signs and symptoms. Recall bias of asthma symptoms may affect overall analysis

in two ways: 1) by those children/parents who are poor perceivers of airway obstruction;
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and 2) by those children/parents who are over-perceivers of airway obstruction.

Comparing survey results with the actual clinical picture may reduce some of this bias.

NHANES III guidelines for spirometry were used as "predicted normal values".
Within these guidelines, values used for "Hispanic" populations are limited to those of
Mexican origin. 59 Previous studies have shown that children of Mexican origin may not

be reflective of those children of Puerto Rican heritage. This is an issue for children

enrolled in Easy Breathing(C) because these children tend to be of Puerto Rican ethnicity.

Data from the Hispanic Health and Nutrition Examination Survey and other studies
suggest that asthma may be more common and more severe in Puerto Rican children. 38’ 6669

Consequently, estimates of "normal" lung function may not accurately reflect this

study population.
Conclusion

Although other studies have examined the differences between subjective and
objective measures of asthma severity, this is the first study to examine the overall
(C)
validity of the Easy Breathing Provider Assessment. It is important to note, while

sensitivity and specificity were not as high as hypothesized, the first four questions of the
Provider Assessment demonstrated statistical significance in capturing the majority of
children with

asthma, regardless of severity.

These findings confirm that asthma is a

complex disease process with symptoms varying from person to person: no one question

(or symptom) serves as an individual marker for asthma severity.
Whenever possible, objective measures should be considered to rule out other
disease processes and to assist in properly classifying asthma severity. When objective
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(C)
measures are not readily available, the Easy Breathing Provider Assessment is an

effective tool to use in determining asthma severity.

The Future ofEasy Breathing

(C)

(C)
The Easy Breathing Provider Assessment demonstrates moderate agreement

between how clinicians use the program versus how it is intended to be used; however,
the Provider Assessment is still affected by clinician unwillingness/inability to properly

classify asthma severity as shown in Table 8. Future studies could glean information on
the reasons behind this particular limitation, determine if the clinicians enrolled in Easy

Breathing differ from those from previous studies, and whether changes could be made to
improve adherence rates.

An Asthma Center study is currently under way to determine 1) If there are
clinician and/or practice dynamics that limit clinicians’ ability to adequately manage

asthma; and 2) To determine if providing interventions that focus on these dynamics will
improve adherence to the program.

Beyond the scope of this particular project is the

need to determine what specific interventions improve adherence and, in particular, if
educational programs need to be directed toward clinicians, staff, and/or patients.

In addition, studies that analyze the classification scheme as set forth by the

NAEPP guidelines and that provide recommendations for more specific symptom
frequencies would help in determining if changes to this classification scheme would
improve classification of asthma severity.
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Aloendix A: Fitures.
(C)
Figure 1. Easy Breathing Survey

1. Has your child had wheezing or whistling in the chest at any time in the last 12 months? Yes No
Yes No

2. Has your child awakened at night because of coughing in the last 12 months?
3. Has your child had coughing, wheezing, or shortness of breath with exercise or
activity and had to stop because of these symptoms at any time in the last 12 months?

Yes No

4. When your child has a cold, does the cough usually last more than 10 days?

Yes No

5. Has anyone told you your child has asthma?
6. Is your child taking any medicines, pills or inhalers for asthma?

Yes No

Yes No

7. What is your child’s ethnic origin?
African American

Hispanic/Mexican

Asian or Pacific Islander Caribbean/Virgin Islander White/Caucasian
Hispanic/Cuban Hispanic/Other Other
Hispanic/Puerto Rican

Is your child exposed to any of the following more than 2fimes/wek:

Yes
Cigarette or Cigar Smoke
Cockroaches
Yes
Rodents (mice or rats)
Yes
Pets
Yes
At home, type of pet (circle all): Dog
At school or day care, type of pet: Dog

No
No
No
No
Cat
Cat

If yes, who smokes
Fireplace/Woodburning Stove Yes No
Yes No
Dust (excessive)
Yes No
Gas Stove
Rodent Other
Bird
Rodent Other
Bird

(C)
Figure 2. Easy Breathing Provider Assessment (New Diagnosis):

Column 2

Column 3

Column 4

<2x/wk

>2x/wk <qd

Daily

Continuously

<3x/mo

>2x/mo

>lx/wk

>4x/wk

None

Occasionally

Some

Always

0- <2x/wk

> 2x/wk <qd

qd

>qd

0-2

>2

>3

>4

None

3-5

6-8

>8

Mild
intermittent

Mild
Persistent

Moderate
Persistent

Persistent

Column

Frequency of episodes of cough, wheeze,
shortness of breath
Frequency of nocturnal symptoms
Exercise impairment even with
pretreatment with beta-agonist
Use ofbeta-agonist (for symptoms not
related to exercise)
Use of prednisone therapy in past year
School Absenteeism for asthma past year
(days/month)
Asthma Severity is
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